These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31345066)

  • 1. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review.
    Shlofmitz E; Iantorno M; Waksman R
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e007023. PubMed ID: 31345066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.
    Waksman R; Iantorno M
    Curr Cardiol Rep; 2018 Oct; 20(12):140. PubMed ID: 30350271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
    Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.
    Kokkinidis DG; Prouse AF; Avner SJ; Lee JM; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):285-299. PubMed ID: 29024274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents.
    Song L; Mintz GS; Yin D; Yamamoto MH; Chin CY; Matsumura M; Fall K; Kirtane AJ; Parikh MA; Moses JW; Ali ZA; Shlofmitz RA; Maehara A
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1115-1124. PubMed ID: 28281026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study.
    Sabbah M; Kadota K; El-Eraky A; Kamal HM; Abdellah AT; El Hawary A
    Int J Cardiovasc Imaging; 2017 Oct; 33(10):1463-1472. PubMed ID: 28444549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-coated balloons for the treatment of in-stent restenosis in diabetic patients: A review of currently available scientific data.
    Minacapelli A; Piraino D; Buccheri D; Cortese B
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):E20-E27. PubMed ID: 28544361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
    Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.
    Xu B; Qian J; Ge J; Wang J; Chen F; Chen J; Wei M; Chen Y; Yang Y; Gao R;
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():624-9. PubMed ID: 26775079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty.
    Oh PC; Suh SY; Kang WC; Lee K; Han SH; Ahn T; Shin EK
    Korean J Intern Med; 2016 May; 31(3):501-6. PubMed ID: 26951915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-stent Restenosis.
    Lee MS; Banka G
    Interv Cardiol Clin; 2016 Apr; 5(2):211-220. PubMed ID: 28582205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and management of drug-eluting stent in-stent restenosis.
    Parfrey S; Siu V; Graham JJ; Vijayaraghavan R; Li C; Pang J; Kalra S; Džavík V; Wijeysundera HC; Bagai A;
    Curr Opin Cardiol; 2023 Sep; 38(5):433-440. PubMed ID: 37477129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Eluting Stent Restenosis: Modern Approach to a Classic Challenge.
    Donisan T; Madanat L; Balanescu DV; Mertens A; Dixon S
    Curr Cardiol Rev; 2023; 19(3):e030123212355. PubMed ID: 36597603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.